Elevated expression levels of TLR4 or it’s adaptor protein MyD88 have been associated with reduced survival outcome in HGSOC patients [6, 8, 15, 23–25], while therapeutic targeting of TLR4 has been shown to restore paclitaxel sensitivity in ovarian cancer cell models [6, 16]. Here, MYD88 is linked to ovarian carcinoma.